Therapeutic potential of innate lymphoid cells for multiple myeloma therapy

7Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.

Abstract

Innate lymphoid cells (ILCs) are a recently identified family of lymphocyte-like cells lacking a specific antigen receptor. They are part of the innate immune system. They play a key role in tissue homeostasis and also control inflammatory and neoplastic processes. In response to environmental stimuli, ILCs change their phenotype and functions, and influence the activity of other cells in the microenvironment. ILC dysfunction can lead to a wide variety of diseases, including cancer. ILC can be divided into three subgroups: ILC Group 1, comprising NK cells and ILC1; Group 2, including ILC2 alone; and Group 3, containing Lymphoid Tissue inducers (LTi) and ILC3 cells. While Group 1 ILCs mainly exert antitumour activity, Group 2 and Group 3 ILCs are protumorigenic in nature. A growing body of preclinical and clinical data support the role of ILCs in the pathogenesis of multiple myeloma (MM). Therefore, targeting ILCs may be of clinical benefit. In this manuscript, we review the available data on the role of ILCs in MM immunology and therapy.

Cite

CITATION STYLE

APA

Szudy-Szczyrek, A., Ahern, S., Kozioł, M., Majowicz, D., Szczyrek, M., Krawczyk, J., & Hus, M. (2021, October 1). Therapeutic potential of innate lymphoid cells for multiple myeloma therapy. Cancers. MDPI. https://doi.org/10.3390/cancers13194806

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free